Corcept Therapeutics Incorporated (CORT)

Corcept Shares Rise More Than 60% in Three Months: Here's Why

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.

3 Reasons Growth Investors Will Love Corcept (CORT)

Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

• 
  3 Reasons Why Growth Investors Shouldn't Overlook Merit Medical (MMSI)

  Zacks
• 
  Corcept Shares Rise More Than 60% in Three Months: Here's Why

  Zacks